Novel long acting rhtsh superagonist analogs for improved diagnostic imaging, thyroglobulin stimulation and therapy of thyroid cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA224376
- Recipient
-
Trophogen, LLC UEI JSYSU447VRP3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,532,780
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Funding
-
- $2,187,695.00 Federal
- $345,085.00 Non-federal
- Place of performance
- Rockville, MD 20850, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $345,085 | $0 | |
| Amendment | $345,085 | $345,085 | |
| Amendment | $433,685 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $778,770 | $0 | |
| Original award | $285,070 | $0 |
Quick answers
Who received award R44CA224376?
R44CA224376 was awarded to Trophogen, LLC by National Cancer Institute (National Institutes of Health) on August 1, 2018.
How much is award R44CA224376 worth?
$2,532,780 has been obligated on R44CA224376: $2,187,695 in federal funding and $345,085 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award